Future Proofing Peptide MAM By Ensuring Scalability And Deployment

By Scott J. Berger, Sr. Manager, Waters Corporation

The development of biotherapeutics continues to accelerate with their potential to revolutionize disease treatment in areas not adequately addressed by small molecule therapeutics. However, the complexity of these macromolecules and the range of potential modification variants (attributes) creates an interesting analytical challenge for scientists tasked with their characterization and then with monitoring those attributes important to their safety and efficacy.

Liquid-chromatography-mass spectrometry (LC-MS) is a critical methodology for accurately characterizing the wide-ranging variability of biologics. This knowledge can be transformed into single multiplexed assays for monitoring attributes across development, manufacturing, and release. In this blog we review how LC-MS-based peptide multi-attribute method (MAM) workflows, like those offered by the Waters BioAccord LC-MS System, have been gaining interest across development and commercialization organizations work to accomplish this.